The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
Abstract
BACKGROUND AND PURPOSE While the combination of stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain metastases (BM), there is a paucity of prospective data to validate both the safety and efficacy, as well as the optimal timing of these two therapies relative to one another. METHODS A PICOS/PRISMA/MOOSE selection protocol was used to identify 17 studies across 15 institutions in 3 countries. Inclusion criteria were patients: diagnosed with BM; treated with SRS/ICI, either concurrently or non-concurrently; with at least one of the primary or secondary outcome measures reported. Weighted random effects meta-analyses using the DerSimonian and Laird method were performed. The primary outcome was 1-year overall survival (OS). Secondary outcomes were 1-year local control (LC), 1-year regional brain control (RBC), and radionecrosis incidence. RESULTS A total of 534 patients with 1,570 BM were included. The 1-year OS was 64.6% and 51.6% for concurrent and non-concurrent therapy, respectively (p < 0.001). Local control at 1-year was 89.2% and 67.8% for concurrent and non-concurrent therapy, respectively (p = 0.09). The RBC at 1-year was 38.1% and 12.3% for concurrent and ICI administration prior to SRS, respectively (p = 0.049). The overall incidence of radionecrosis for all studies was 5.3%. CONCLUSIONS Concurrent administration of SRS/ICI may be associated with improved safety and efficacy versus sequential therapy. These findings, however, are hypothesis-generating and require further validation by ongoing and planned prospective trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Barker, F. G., Deming, R., Burri, S. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.9839 · Cited by 1,671
Self-citationSperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425
Self-citationLee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., Bhatt, A., Jensen, A. W., Brown, P. D., Shih, H., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.025 · Cited by 985
Self-citationLugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Revisiting the Mechanisms of CNS Immune Privilege
Louveau, A., Harris, T. H., & Kipnis, J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.006 · Cited by 682
Maximizing Tumor Immunity With Fractionated Radiation
Schaue, D., Ratikan, J. A., Iwamoto, K. S., & McBride, W. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.049 · Cited by 567
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
Sampson, J. H., Carter, J. H., Friedman, A. H., & Seigler, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0011 · Cited by 560
Prognostic factors for survival in melanoma patients with brain metastases
Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W., Hwu, P., & Bedikian, A. (2011) · Cancer · doi:10.1002/cncr.25634 · Cited by 548
Chakraborty, M., Abrams, S. I., Camphausen, K., Liu, K., Scott, T., Coleman, C. N., & Hodge, J. W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6338 · Cited by 467
Determinants of Outcome in Melanoma Patients With Cerebral Metastases
Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.140 · Cited by 445
Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.004 · Cited by 390
Chen, L., Douglass, J., Kleinberg, L., Ye, X., Marciscano, A. E., Forde, P. M., Brahmer, J., Lipson, E., Sharfman, W., Hammers, H., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.11.041 · Cited by 329
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288
Ipilimumab and radiation therapy for melanoma brain metastases
Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. (2013) · Cancer Medicine · doi:10.1002/cam4.140 · Cited by 280
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H. H. M., Etame, A. B., Weber, J. S., & Gibney, G. T. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 239
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., Fenstermaker, R. A., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0166 · Cited by 231
Qian, J. M., Yu, J. B., Kluger, H. M., & Chiang, V. L. S. (2016) · Cancer · doi:10.1002/cncr.30138 · Cited by 212
Patel, K. R., Shoukat, S., Oliver, D. E., Chowdhary, M., Rizzo, M., Lawson, D. H., Khosa, F., Liu, Y., & Khan, M. K. (2017) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000199 · Cited by 192
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835f3d90 · Cited by 178
The treatment of brain metastases in melanoma patients
Bafaloukos, D., & Gogas, H. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.05.001 · Cited by 163
Neurocognitive Decline Following Radiotherapy: Mechanisms and Therapeutic Implications
Pazzaglia, S., Briganti, G., Mancuso, M., & Saran, A. (2020) · Cancers · doi:10.3390/cancers12010146 · Cited by 130
Ahmed, K. A., Kim, S., Arrington, J. A., Naghavi, A. O., Dilling, T. J., Creelan, B., Antonia, S. J., Caudell, J. J., Harrison, L. B., Sahebjam, S., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2437-5 · Cited by 129
Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, Å., Chan, T. A.-T., Yamada, Y. J., & Beal, K. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0282-x · Cited by 120
Williams, N. L., Wuthrick, E. J., Kim, H. J., Palmer, J. D., Garg, S., Eldredge-Hindy, H., Daskalakis, C., Feeney, K. J., Mastrangelo, M. J., Kim, L. J., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.028 · Cited by 118
Choong, E. S., Lo, S., Drummond, M., Fogarty, G. B., Menzies, A. M., Guminski, A. D., Shivalingam, B., Clarke, K., Long, G. V., & Hong, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.007 · Cited by 106
Cohen‐Inbar, O., Shih, H.-H., Xu, Z., Schlesinger, D. J., & Sheehan, J. P. (2017) · Journal of neurosurgery · doi:10.3171/2016.9.jns161585 · Cited by 96
Self-citationIpilmumab and cranial radiation in metastatic melanoma patients: a case series and review
Schoenfeld, J. D., Mahadevan, A., Floyd, S., Dyer, M. A., Catalano, P. J., Alexander, B. M., McDermott, D. F., & Kaplan, I. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0095-8 · Cited by 94
Skrepnik, T., Sundararajan, S., Cui, H., & Stea, B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1283461 · Cited by 88
Bernstein, M. B., Garnett‐Benson, C., Zhang, H., Velcich, A., Wattenberg, M. M., Gameiro, S. R., Kalnicki, S., Hodge, J. W., & Guha, C. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1578 · Cited by 87
Gaudy‐Marqueste, C., Dussouil, A.-S., Carron, R., Troin, L., Malissen, N., Loundou, A., Monestier, S., Mallet, S., Richard, M. A., Régis, J. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.017 · Cited by 83
Kamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 78
Acharya, S., Mahmood, M., Mullen, D. F., Yang, D., Tsien, C. I., Huang, J., Perkins, S. M., Rich, K. M., Chicoine, M. R., Leuthardt, E. C., et al. (2017) · Advances in Radiation Oncology · doi:10.1016/j.adro.2017.07.003 · Cited by 73
Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats
Nakata, H., Yoshimine, T., Murasawa, A., Kumura, E., Harada, K., Ushio, Y., & Hayakawa, T. (1995) · Acta Neurochirurgica · doi:10.1007/bf01411440 · Cited by 68
NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain
Prins, R. M., Vo, D. D., Khan-Farooqi, H., Yang, M., Soto, H., Economou, J. S., Liau, L. M., & Ribas, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8448 · Cited by 63
The inflammatory microenvironment in brain metastases: potential treatment target?
Berghoff, A. S., & Preusser, M. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.06.03 · Cited by 61
Recovering the raw data behind a non-parametric survival curve
Liu, Z., Rich, B., & Hanley, J. A. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-151 · Cited by 55
The central nervous system: privileged by immune connections
Kipnis, J., & Filiano, A. J. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.152 · Cited by 51
Yusuf, M. B., Amsbaugh, M. J., Burton, E., Chesney, J. A., & Woo, S. Y. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.01.101 · Cited by 50
Melanoma in the brain: biology and therapeutic options
Gibney, G. T., Forsyth, P. A., & Sondak, V. K. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328352dbef · Cited by 48
Hadi, I., Roengvoraphoj, O., Bodensohn, R., Hofmaier, J., Niyazi, M., Belka, C., & Nachbichler, S. B. (2020) · Radiation Oncology · doi:10.1186/s13014-020-1485-8 · Cited by 42
Epidemiology, Treatment, and Complications of Central Nervous System Metastases
Pruitt, A. A. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000551 · Cited by 36
Bersanelli, M., Lattanzi, E., D’Abbiero, N., Buti, S., Leonetti, A., Can�, M., Trapani, S., Gravina, G., Porzio, G., Cannita, K., et al. (2019) · Biomedical Reports · doi:10.3892/br.2019.1265 · Cited by 14
McClelland, S., Lautenschlaeger, T., Zang, Y., Hanna, N. H., Shiue, K., Kamer, A. P., Agrawal, N., Ellsworth, S. G., Rhome, R. M., & Watson, G. A. (2020) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2020.04.007 · Cited by 14
Cited by
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 832
Self-citationLe Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Metellus, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.016 · Cited by 592
Current approaches to the management of brain metastases
Suh, J. H., Kotecha, R., Chao, S. T., Ahluwalia, M. S., Sahgal, A., & Chang, E. L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0320-3 · Cited by 553
Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain
Milano, M. T., Grimm, J., Niemierko, A., Soltys, S. G., Moiseenko, V., Redmond, K. J., Yorke, E., Sahgal, A., Xue, J., Mahadevan, A., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.08.013 · Cited by 402
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 368
Metadata
- Authors
- Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M.
- Venue
- Radiotherapy and Oncology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 130
- Pages
- 104-112
- ISSN
- 0167-8140 (ISSN-L)
- OpenAlex
- W2890381929
- Cited by
- 264
- References
- 65
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.